• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by EVP and CFO Vanhimbergen Robert M

    7/14/26 4:15:12 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    VanHimbergen Robert M

    (Last)(First)(Middle)
    C/O ELANCO ANIMAL HEALTH INCORPORATED
    450 ELANCO CIRCLE

    (Street)
    INDIANAPOLIS INDIANA 46221

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Elanco Animal Health Inc [ ELAN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    EVP and CFO
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    07/10/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Deferred Stock Units(1)07/10/2026A7.938 (2) (2)Common Stock7.938$24.82116.7886D
    Explanation of Responses:
    1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
    2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.
    /s/ Amy C. Seidel, as Attorney-in-Fact for Robert M. VanHimbergen07/14/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $ELAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    4/15/2026$30.00Buy
    Citigroup
    1/22/2026Neutral → Overweight
    Piper Sandler
    12/9/2025$30.00Overweight
    Barclays
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    11/19/2025$25.00Hold → Buy
    Argus
    10/7/2025$24.00Neutral → Overweight
    Analyst
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    6/26/2025Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $ELAN
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Elanco Animal Health Incorporated

    SCHEDULE 13G - Elanco Animal Health Inc (0001739104) (Subject)

    7/14/26 1:27:07 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SD filed by Elanco Animal Health Incorporated

    SD - Elanco Animal Health Inc (0001739104) (Filer)

    5/27/26 5:09:19 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Elanco Animal Health Inc (0001739104) (Filer)

    5/27/26 5:00:57 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Modi Rajeev A. bought $99,939 worth of shares (4,911 units at $20.35), increasing direct ownership by 3% to 160,812 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    5/19/26 4:39:20 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $99,843 worth of shares (4,971 units at $20.09) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    5/19/26 4:38:26 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    7/14/26 4:15:39 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP and CFO Vanhimbergen Robert M

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    7/14/26 4:15:12 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    7/14/26 4:14:31 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Elanco Animal Health with a new price target

    Citigroup initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $30.00

    4/15/26 8:08:24 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by Piper Sandler

    Piper Sandler upgraded Elanco Animal Health from Neutral to Overweight

    1/22/26 8:20:23 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Elanco Animal Health with a new price target

    Barclays initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $30.00

    12/9/25 8:46:01 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)

    Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro:Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours of treatment.iKills the lone star tick (Amblyomma americanum) within 12 hours of infestation; achieving the fastest3 initial speed of tick kill compared to the competition.iiAchieves a rapid speed of kill4 on Day 0 and on Day 28, with no statistically significant drop-off in performance at the end of the dosing period.i,iiOutlasts competitors whose speed of kill2,4 performance declined at the end of the month.i,iiINDIANAPOLIS, July 22, 2026 /PRNewswire/ -- When it comes to killing ticks, veterin

    7/22/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement

    INDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/news-events/events-presentation. A replay will also be available on the website shor

    7/8/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health

    New corporate venture capital platform will invest to advance therapeutics, technologies and One Health solutionsINDIANAPOLIS, June 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced plans to establish Elanco Ventures, a dedicated corporate venture capital (CVC) platform designed to support, invest and advance innovation in animal health. To be backed by a $25 million multi-year commitment, Elanco Ventures will initially focus on strategic investments in therapeutic advancements and supportive technologies across the animal health sector."From pets to protein – the animal health industry has

    6/18/26 7:26:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    7/8/24 4:32:39 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/13/24 2:08:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/12/24 4:01:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    View All

    National Veterinary Associates Appoints Todd S. Young as Chief Financial Officer

    National Veterinary Associates (NVA) announced the appointment of Todd S. Young as Chief Financial Officer, effective May 1, 2026. Young will serve on the company's executive leadership team and report to Chief Executive Officer John Bruno. "I am thrilled to welcome Todd to NVA," said Bruno. "He has spent his career leading world-class finance teams in human and animal healthcare, and his public company experience and deep industry knowledge are exactly what we need as we enter our next phase of growth." Young brings more than 25 years across human and animal healthcare, including more than a decade as a public company CFO. Most recently, he served as CFO of Acadia Healthcare (NASDAQ:AC

    4/24/26 9:00:00 AM ET
    $ACHC
    $ELAN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Elanco executive appointed as Neurizon's Board Observer

    MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited ((ASX: NUZ &, NUZOA, OTCQB:NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE:ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative. The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follo

    11/26/25 6:15:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    Banks
    Finance
    Savings Institutions
    Biotechnology: Pharmaceutical Preparations

    $ELAN
    Financials

    Live finance-specific insights

    View All

    Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement

    INDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/news-events/events-presentation. A replay will also be available on the website shor

    7/8/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Reports First Quarter 2026 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio TargetFirst Quarter 2026 Financial Results:Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growthReported Net Income of $57 million, Adjusted Net Income of $204 millionAdjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5%Reported EPS of $0.11, Adjusted EPS of $0.40Net leverage ratio of 3.5x Adjusted EBITDAFull Year 2026 Guidance:Raising innovation revenue target to $1.2 billionRaising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growthRaising Adjusted EBITDA to $975 million to $1,005 million, a year-over-y

    5/6/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement

    INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.asp

    4/16/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care